Summary: Some effects of liposome-incorporated amphotericin B on the permeability of the human erythrocyte membrane to potassium and sodium ions is reported. The influence of cholesterol and amphotericin B in causing a shift towards smaller and larger liposomes, respectively, is also described. Phosphatidylcholine liposomes containing amphotericin B in a molar ratio of 7.4 + 0.1 (mean ± SD) antibiotic to 1000 phospholipid reduced the initial rates of K + and Na + transport across the erythrocyte membrane to 40 + 2.6% and 0%, respectively, of their rates in the presence of comparable concentrations of free amphotericin B. Amphotericin B incorporated into liposomes (8.2 + 0.15 μηιοί antibiotic per 1000 μηιοί total lipid) composed of cholesterol and phosphatidylcholine (in a molar ratio of 3 : 7) reduced the initial rate of K + transport to 19 ± 0.8% of its value measured in the presence of a comparable concentration of free antibiotic. These results suggest that liposomes containing specified amounts of amphotericin B, especially liposomes also containing cholesterol in addition to phosphatidylcholine, could be used as a method of controlling K+ transport across the erythrocyte and possibly other types of cellular membranes, thereby limiting antibiotic toxicity to some mammalian tissues.
Introduction
Amphotericin B and nystatin are highly effective, but toxic, polyene macrolide antibiotics, used in the treatment of a wide range of fungal infections (1) . They achieve their fungicidal and lytic activities by complexing with the sterols available in plasma membranes (2 -4), thus forming transmembrane channels, which allow the efflux of vital cations such as potassium (4, 5) . They inhibit, however, the exchange of some metabolically important anions such as phosphate and sulphate (6, 7) . In addition, the formation of channels leads to disruption of sterol-phospholipid interactions in membranes (8) . These combined effects of this class of ionophoric antibiotics lead eventually to cell lysis and death. The ability of intravenously administered amphotericin B to form channels by interaction with cholesterol in mammalian plasma membranes (4) , but with a lower affinity than with fungal ergosterol (4, 28) , could be the basis for its haematopoietic, nephrotic and central nervous system toxicities (9 -11) . Since amphotericin B is the drug of choice for most systemic mycoses, arising as complications in patients with haematological malignancies (12, 13) and in immunocompromised patients (14, 15) , attempts have been made to reduce its toxicity and to improve its therapeutic efficacy by incorporating it into liposomes prior to its intravenous injection (16) (17) (18) (19) (20) .
Multilamellar liposomes (21 -23) have been used as carriers of antimicrobial (24) , antiparasitic (25) and antineoplastic drugs (26) to improve their therapeutic index. Liposome-incorporated amphotericin B has been studied in a variety of experimental infections. New et al. (16) , for example, showed that liposomeincorporated amphotericin B was less toxic and more active against experimental Leishmaniasis than the free drug. A lower toxicity and an equal therapeutic efficacy were observed by Taylor et al. (18) against experimental histoplasmosis, by Graybill et al. (17) against experimental cryptococcosis, and by LopezBerestein (27) and Lopez-Berestein et al. (19, 20) against experimental candidiasis.
The purpose of this study is to investigate the possible reduction of cell damage and toxicity toward human erythrocytes, but with obvious implications for other cell types, by using liposome-incorporated polyene antibiotics in conjunction with or without free therapeutic steroid derivatives. In this work, liposomes were used as carriers for specified amounts of amphotericin B or nystatin.
Materials and Methods

Materials
Human blood, with added standard citrate-dextrose-adenine solution, was kindly supplied by the blood bank of King Khalid University Hospital, Riyadh. Amphotericin B was obtained from Sigma Chemical Co., Kingston upon Thames, Surrey, U.K. Nystatin and ouabain were purchased from Windsor Laboratories, Slough, Berkshire, U.K. L-a-Phosphatidylcholine from egg yolk was provided by Calbiochem Corporation, San Diego, U.S.A. Cholesterol was supplied by Riedel-de Haen, Hannover, Germany. Digitoxin and digitoxigenin were obtained from BDH Chemicals, Poole, Dorset and Koch-Light Laboratories, Colnbrook, Bucks, U.K., respectively. Hydrocortisone sodium succinate in its clinical formulation was a product of Upjohn S. A., Puurs, Belgium. All other reagents were analytical grade or better and were obtained from BDH Chemicals.
Methods
Preparation of liposomes
A solution of phosphatidylcholine in methanol : chloroform (2 :1, by vol.), was evaporated to dryness under nitrogen. The resulting pellet was suspended in an isotonic solution of 9 g/1 NaCl by hand shaking for a few minutes to form liposomes. Liposomes containing cholesterol were prepared by the same method at a molar ratio of cholesterol to phospholipid of 3 : 7. Liposomes prepared in this way were sedimented by centrifugation at 700 g in a MSB Coolspin centrifuge, then suspended in Tris-buffered saline (5 mmol/1 Tris, 4 mmol/1 KC1,146 mmol/1 NaCl, pH 7.4). The amounts of cholesterol and phospholipid in the liposomes were estimated by determining the amounts of these constituents in both the supernatant and the pellet. The size distribution of the prepared liposomes was determined using an electronic particle size analyser (Coulter Counter, model ZM). This device simultaneously enumerates the number of particles in each of sixteen different sizes based on average volume.
Incorporation of antibiotics into liposomes
Prior to incorporation, antibiotics were sonicated in 9 g/1 NaCl for 2 χ 10 s intervals on ice using a MSB Soniprep 150 at an amplitude of 10 μηι. An aliquot of the antibiotic preparation was taken prior to and after sonication to determine the size distribution of antibiotic particles as described above. Sonicated antibiotic suspensions were incubated with liposomes in Tris buffered saline at a molar ratio of antibiotic to liposomal phospholipids of 1 to 100 for 25 min at room temperature. To estimate the amount of antibiotic incorporated into liposomes, the unincorporated particulate amphotericin B or nystatin was separated from liposomes by centrifuging the antibiotic lipid mixtures for 10 min at 500 g. The quantity of antibiotic incorporated into liposomes was estimated by dissolving the pellet, after washing it once with Tris buffered saline, in methanol : chloroform (2:1, by vol.), then measuring the absorbance at 405 nm and 303 nm for amphotericin B and nystatin, respectively, using pure antibiotics as standards. Phospholipid and cholesterol in the supernatants were determined by the methods of Chen et al. (29) and Leffler & McDougal (30) , respectively. The size distribution of liposome-incorporated antibiotic was determined as described above.
Measurement of potassium and sodium transport in erythrocytes treated with liposome-incorporated antibiotics
Erythrocytes were prepared by washing normal human blood in Tris buffered saline and centrifuging at 1000 g for 10 min at 4 °C. After removal of the buffy coat, the erythrocytes were washed twice again with Tris buffered saline as above. Washed erythrocytes were pre-incubated with liposomes containing the antibiotic, or with the free antibiotic solubilized in dimethyl sulphoxide, using the same antibiotic concentration in both cases. Pre-incubation was carried out for 15 min in Tris buffered saline at a haematocrit value of 0.45 and 37 °C, in the presence or absence of digitoxin, digitoxigenin, or hydrocortisone succinate. Controls were performed in the presence or absence of free antibiotic, and with empty liposomes plus free cholesterol or free phosphatidylcholine.
In order to measure sodium and potassium transport, samples were removed from the reaction medium at various time intervals and centrifuged at 2000 g for 0.5 min. Aliquots were taken from the supernatant for haemoglobin determination using a Boehringer Mannheim haemoglobin kit. Further aliquots of the supernatant were taken and subsequently diluted with Tris buffered saline for K + determination, using a Dr. Lange M7D flame photometer. Na + was determined with a Pye Unicam SP9 atomic absorption spectrophotometer, in aliquots of supernatants diluted with 6% isobutanol. All concentrations of the antibiotic, together with a control containing dimethyl sulphoxide where necessary, were examined in duplicate in one experiment.
Results
Effect of cholesterol on liposomal size distribution
The size distribution of the prepared liposomes was assessed using a Coulter Counter, model ZM. The average diameter of about 95% of the phosphatidylcholine liposomes and those composed of both cholesterol and phosphatidylcholine was less than 2.88 μηι ( fig. la) . However, the total number of phosphatidylcholine liposomes containing cholesterol was 8.3 ± 0.6% (mean ± SD) less than that of phosphatidylcholine liposomes lacking cholesterol. According to the phospholipid assay, there was no increase in the residual amount of free un-incorporated phosphatidylcholine molecules when liposomes were formed from cholesterol and phosphatidylcholine in a molar ratio of 3 : 7. The volume for each average liposome diameter was calculated from the frequency data, which are given in figure la. . Diameter calibration was performed using latex particles, number 9316007 (Coulter electronics), using an aperture diameter of 30 μηι, which spanned a total diameter range of 0.6 -18 μηι. The data shown correspond to 250 μΐ of liposomes containing 63 μπιοί of liposomal phosphatidyl-choline or 19 μηιοί of liposomal cholesterol and 44 μηιοί of phosphatidylcholine. Liposomes were diluted 800 χ with 0.4 mmol/1 sodium pyrophosphate, pH 7.4, prior to counting. The bottom frame (b) was drawn from calculations derived from the data shown in the top frame (a) as described in Materials and Methods. Each point represents the mean of five different determinations.
less than that of liposomes lacking cholesterol, presumably partly due to the smaller total number of liposomes of the former type. Particles larger than 2.88 μηι in diameter are expected to be mainly aggregates of multilamellar liposomes.
Size distribution of amphotericin Β particles
The availability of particles of amphotericin B, and their size distribution in Tris buffered saline, was demonstrated using a Coulter Counter, model ZM ( fig. 2) . The average diameter of more than 95% of amphotericin B particles, prepared from sonicated or unsonicated medium, was less than 3.45 μηι ( fig. 2a) . The particles counted are most probably aggregates of micelles, as individual micelles are too small to be The average diameter distribution of amphotericin B was measured under conditions similar to those described in the legend of figure la except that a pre-set gain of 2.0, a calibration factor of 6.35, a calibration volume of 2.1 μηι 3 and an aperture resistance of 19.3 kQ were used. Diameter calibration was performed using latex particles, number 9316008 using an aperture diameter of 50 μηι which spanned a total range of 0.8 to 30 μιη. The data shown correspond to 250 μΐ of 10 μπιοΐ/ΐ stock of sonicated (·) or unsonicated (A) amphotericin B. The amphotericin B sample taken was diluted 400 χ with 0.4 mol/1 sodium pyrophosphate, pH 7.4, prior to counting. The bottom frame (b) was drawn from calculations derived from the data shown in the top frame (a) as described in Materials and Methods. Each point represent the mean of four different determinations.
quantitated by this method. The total number of amphotericin B particles was increased by 22 ± 1.7% upon sonication. The volume at each average diameter of amphotericin B particles was calculated from the frequency data which are given in figure 2a. Total volume distribution analysis ( fig. 2b) showed that sonication of amphotericin B dispersions led to the formation of a less heterogeneous population of particles ( fig. 2b) . Moreover, statistical analysis, in which the data of figure 2b were summated, showed that sonication of amphotericin B dispersions caused a shift toward smaller particles. In spite of their higher total count, sonicated amphotericin B particles had about the same total volume as those of unsonicated ones.
Incorporation of amphotericin B into liposomes and its effect on liposomal size distribution To achieve optimal conditions for incorporating amphotericin B or nystatin into liposomes, antibiotic dispersions were sonicated, then incubated with unsonicated liposomal preparations. The unpartitioned antibiotic portion was separated from antibioticloaded liposomes at low centrifugal force. The centrifugation of mixtures of sonicated amphotericin B and sonicated liposomes, or unsonicated amphotericin B and unsonicated liposomes did not efficiently separate the un-incorporated portion of the antibiotic from the liposome-incorporated antibiotic. The molar ratio of incorporated antibiotic to liposomal lipid was found to be 7.4 ± 0.1/1000 and 8.2 + 0.15/1000 in phosphatidylcholine and cholesterol liposomes, respectively. Much lower percentages of nystatin were found to be incorporated into liposomes. The molar ratio of antibiotic to membrane lipid was found to be 2.5 ± 0.1/1000 and 3.0 ± 0.12/1000 in phosphatidylcholine and phosphatidylcholine cholesterol liposomes, respectively.
The average diameter distribution of liposomes containing amphotericin B ( fig. 3a) revealed that the average diameter of more than 95% of liposomes, containing or lacking cholesterol, was less than 3.6 μπι. The volume at each average liposome diameter was calculated from the frequency data given in figure  3a . Total volume distribution analysis, in which the data of figure 3b were summated (fig. 3b) , showed that the incorporation of amphotericin Β into cholesterol-containing liposomes caused a shift toward larger liposomes. Although their total count was decreased by 9.7% ± 1.7%, the total volume of these liposomes was 14.6 ± 1.1% greater than that of cholesterol-lacking liposomes loaded with amphotericin Β (fig. 3b) .
Permeability of the human erythrocyte membrane to cations under the influence of liposome-incorporated amphotericin Β Incorporation of sonicated amphotericin Β into phosphatidylcholine liposomes at a molar antibiotic to phospholipid ratio of 7.4 to 1000 reduced the initial rates of K + and Na + transport across the erythrocyte membrane to 40 ± 2.6% ( fig. 4a) and 0% (fig. 4b) , respectively, of their rates in the presence of comparable concentrations of free amphotericin B. Despite a more efficient incorporation of amphotericin Β into liposomes (8.2 μιηοΐ antibiotic per 1000 μπιοί lipid), at a molar ratio of cholesterol to phosphotidylcholine of 3 : 7, the initial rate of K+ transport was reduced to 19 ± 0.8% of its value with a comparable concentration of free antibiotic ( fig. 4a ). The effects of incorporating higher concentrations of amphotericin B into liposomes, on K + and Na + transport, were not easy to assess. This was because the incubation of liposomes, even with sonicated antibiotic preparations of more than 10 μηιοΐ/ΐ concentration, led to a partial precipitation of the un-incorporated antibiotic portion with liposomes, thus preventing an accurate assessment of the amount of amphotericin B incorporated into the liposomes. Potassium and sodium ion transport were further investigated by co-incubating antibiotic-free phosphatidylcholine cholesterol liposomes and free cholesterol, to check that the efficacy of cholesterol-containing liposome preparation, in reducing K + transport, was not due to an interaction between amphotericin B and un-incorporated cholesterol which might be attached to the surface of liposomes during their formation. The initial rates of transport of K + or Na + , however, did not seem to be affected by mixing free cholesterol with preformed phosphatidylcholine cholesterol liposomes, at a molar ratio of cholesterol to total liposomal lipids of 5 :100. In addition, neither antibiotic-free phosphatidylcholine liposomes, 12.5 mmol/1 free phosphatidylcholine or 1.5% dimethyl sulphoxide caused any haemolysis or had any effect on the rates of K + or Na + transport. On the other hand, the efficacy of phosphatidylcholine, or cholesterol-phosphatidylcholine (3 : 7) liposomes, in minimizing the initial rate of cation exchange observed with free antibiotic, was reduced in the presence of free steroidal drugs, such as digitoxigenin,by41 ± 3.7% and 22 ± 2.5% respectively ( fig.  5a ). Values in the order of 57 ± 4.1% and 16 ± 1.1% were obtained with digitoxin under the same conditions ( fig. 5b) . Neither digitoxigenin nor digitoxin, however, had any effect on the initial rate of K" 1 " transport in the presence of free amphotericin B alone (figs. 5a and 5b). In addition, hydrocortisone succinate had no effect on the rates of cation fluxes, whether used with free or liposome-incorporated amphotericin B. On the other hand, the initial rates of K + and Na + transport were too low to be measured at the relatively low molar ratios of nystatin to liposomal lipids of 2.5/1000 and 3.0/1000 for phosphatidylcholine and cholesterol-phosphatidylcholine liposomes, respectively. Furthermore, comparably low concentrations of free nystatin failed to show any measurable effect on K + release.
Discussion
The degree of amphotericin B or nystatin incorporation into liposomes appeared to depend on the lipid composition of the liposomes. The amount of amphotericin B or nystatin incorporated into liposomes containing cholesterol was about 11% higher than into liposomes lacking cholesterol. This could be explained in the light of their different affinities for sterols in biological and model membranes (2-4, 31, 32). The relatively low percentage of nystatin, as compared with amphotericin B, incorporated into liposomes may be due to the combined effects of its relatively lower partition coefficient in decane and in the erythrocyte membrane (33) and the lower affinity and effectiveness with which is binds (31, 32) to membrane cholesterol. Moreover, using size distribution analysis with a Coulter Counter, we showed that the formation of liposomes from both phosphatidylcholine and cholesterol led to an 8.3% reduction in the total number of liposomes formed. Nevertheless, the total volume of liposomes containing cholesterol in the range examined was found to be 19% lower that that of liposomes lacking cholesterol. This indicates a shift toward smaller liposomes and vesicles in the former case. The shift toward smaller liposomes may be explained by the known effect of cholesterol in causing tighter packing of phospholipid molecules rich in unsaturated fatty acids (34, 35) , thereby allowing tighter packing of individual lamellae.
The significant increase in the total number of amphotericin B particles upon sonication can be accounted for, at least in part, by sonication-induced dispersion of large amphotericin B particles to form smaller ones. Moreover, size distribution analysis showed that amphotericin B incorporation shifts cholesterol-containing liposomes towards a larger size than cholesterol-lacking liposomes. This might be explained mainly by the ability of amphotericin B to complex cholesterol, thereby rendering it unavailable for interaction with neighbouring phospholipid molecules (8) ; this would cause liposomal lamellae to be less tightly packed than those of cholesterol lacking liposomes.
The effects of liposome-incorporated amphotericin B on the transport profiles of cations across the membrane of the human erythrocyte might be expected to differ from those obtained with free antibiotics (6) . The transport of both cations investigated in this work appeared to undergo significant reduction in the presence of liposome-incorporated amphotericin B, when compared with their rates of transport with comparable concentrations of free antibiotic. The more effective reduction of K + release by cholesterol-phosphatidylcholine liposomes containing amphotericin B was attributed to the relatively tight binding of amphotericin B to the cholesterol available in liposomes. This relatively tight binding effect impedes the exchange of the drug with the erythrocyte membrane, thus reducing the drug's potential to interact with the erythrocyte membrane and consequently to alter its permeability properties, which may lead otherwise to haemolysis. Thus, it appears that the type and nature of lipids constituting the liposomes, used as drug delivery vehicles, play an important role in controlling the rate of drug release and the rate of cation transport (and presumably anion transport) across the human erythrocyte, and possibly other types of mammalian cell membrane. Therefore, the intravenous in-jection of cholesterol-phosphatidylcholine liposomes containing amphotericin B may ensure the gradual release of the antibiotic; this would eliminate the need for routine injections of free amphotericin B in small doses over a period of 3-4 h (36). Moreover, the use of cholesterol-phosphatidylcholine liposomes containing amphotericin should allow the use of a higher single therapeutic dose, while keeping undesirable cation imbalances, and consequently the potential occurrence of haemolytic anaemia, under control.
On the other hand, when incorporated into either type of liposome, the efficacy of amphotericin B in minimizing the initial rate of cation exchange was reduced in the presence of some free steroid drugs such as digitoxigenin and digitoxin, used clinically in the treatment of congestive heart failure. This effect was attributed to the inhibitory action of these drugs on the Na+-K+ pump (37) , allowing Na+ and K+ transport to occur freely across the human erythrocyte membrane, thus causing an ionic imbalance. Nevertheless, the initial rate of transport of K + ions did not seem to be affected when these two cardiotonic steroids were mixed with comparable concentrations of free amphotericin B. This indicates that the Na + -K + pump continues to be responsive to the action of these cardiotonic steroids in the presence of the low amounts of amphotericin B transferred from liposomes to the erythrocyte membrane, but it may fail to respond in the presence of high concentrations of free antibiotic. This is explained by the fact that free amphotericin B has a high partition coefficient in the erythrocyte membrane and causes a significant perturbation of its normal fluidity (33) , which is necessary for the Na + -K + pump to assume its usual conformation and activity, including its ability to bind cardiotonic steroids.
Hydrocortisone succinate is another steroid given with amphotericin B to reduce the febrile reactions that may follow intravenous injection of the latter (1). Although it contains the cholestane ring structure, hydrocortisone succinate was found to have no effect on the rate of K + transport, when used in conjunction with free or with liposome-incorporated amphotericin B. Moreover, it did not seem to complex with amphotericin B, as cholesterol did (2 -4), as evidenced by the UV absorption spectra obtained for amphotericin B in the presence and absence of the drug (UV absorption spectra not shown). This is presumably due to the absence of a hydroxyl group at C 3 in the ring structure of hydrocortisone succinate.
It thus appears that the mechanism by which cell damage and toxicity by amphotericin B, as applied to human erythrocytes and possibly other types of mammalian cells, is mediated by an increased rate of K+ and Na+ transport. This problem can be approached by: a) incorporating amphotericin B into liposomes; b) deriving a method by which specific amounts of amphotericin B can be incorporated in liposomes; c) devising a method which allows the efficient removal of un-incorporated antibiotic;
d) selecting the size distribution of amphotericin B particles; e) incorporating cholesterol as a constituent of the liposomes; f) selecting the optimal concentration of amphotericin B which has a minimal effect on membrane fluidity and consequently on the activity of transport proteins, such as the Na + -K + pump; and g) taking into consideration the effects of any other drugs taken simultaneously with amphotericin B.
Incorporation of amphotericin B in liposomes may result, however, in a reduction in the therapeutic efficacy of the drug.
